News

1703, 2015

VLP Therapeutics Enters Collaboration with Mitsubishi Heavy Industries

2015.03.17|

VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary vaccine technology, today announced that it has entered into a collaboration with Mitsubishi Heavy Industries to facilitate VLP’s on-going research and development of virus like particles.

203, 2015

VLP Therapeutics Wins the 2015 Life Sciences Impact Grant Award from the Montgomery County Department of Economic Development

2015.03.02|

VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary vaccine technology, today announced that it received a 2015 Life Sciences Impact Grant Award from the Montgomery County Department of Economic Development (MCDED).

2503, 2014

VLP Therapeutics Appoints Dr. Ryuji Ueno as Chair and Chief Medical Officer

2014.03.25|

VLP Therapeutics, Inc. ("VLP"), a Rockville-based biotechnology company focusing on the research and development of next generation antibody agents and therapeutic as well as preventive vaccines based upon a novel and proprietary i-αVLP technology (which stands for "inserted alpha virus like particle"), today announced that Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder and former Chair, Chief Executive Officer and Chief Scientific Officer of Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) ("Sucampo") will join VLP as Chair and Chief Medical Officer, effective today.